Does Single Injection Adductor Canal Block Improve Postoperative Analgesia in Patients Receiving Periarticular Local Anesthesia Injections for Total Knee Arthroplasty?

a study on Pain Anesthesia

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California
Dates
study started
estimated completion
Principal Investigator
by Coral Sun, MD

Description

Summary

The purpose of the study is to determine the effect of a single injection adductor canal block (ACB) on pain scores within 24 hours post total knee arthroplasty (TKA).

Keywords

Pain Management pain management for total knee arthroplasty Ketorolac Clonidine Epinephrine Ropivacaine ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline ACB Study + Local infiltration ACB Study Only

Eligibility

You can join if…

Open to people ages 18 years and up

  • Males and Females age 18+ years old having total knee arthroplasty (TKA) at UCI Medical Center
  • American Society of Anesthesiologists physical status I to III

You CAN'T join if...

  • Allergy to local anesthetics
  • Pregnancy
  • Nursing Mothers
  • Children <18 years of age
  • Renal impairment (GFR<60 mL/min/1.73m2)
  • Hepatic Impairment (active hepatitis, elevated AST or ALT, jaundice)
  • Opioid tolerant patients (defined as greater than 30 mg Morphine equivalent consumed daily)
  • Patients that are diabetic with peripheral neuropathy
  • BMI greater than 40

Location

  • University of California, Irvine Medical Center accepting new patients
    Orange California 92868 United States

Lead Scientist at UC Irvine

  • Coral Sun, MD
    Associate Clinical Professor, Anesthesiology and Perioperative Care, School of Medicine

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT02276495
Study Type
Interventional
Participants
Expecting 90 study participants
Last Updated
Contact us about this trial